<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01304498</url>
  </required_header>
  <id_info>
    <org_study_id>V503-009</org_study_id>
    <secondary_id>GDS01C</secondary_id>
    <secondary_id>2010-023393-39</secondary_id>
    <nct_id>NCT01304498</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)</brief_title>
  <official_title>A Randomized, Double-Blinded, Controlled With GARDASIL (Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, Adsorbed)), Phase III Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus (HPV) Vaccine) in Preadolescent and Adolescent Girls (9- to 15-year-old)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:

      • To demonstrate that administration of V503 induces non-inferior Geometric Mean Titers
      (GMTs) (for serum anti-HPV16 and anti-HPV18) compared to GARDASIL.

      Secondary objectives:

        -  To evaluate the tolerability of V503 in 9-15 year-old girls.

        -  To summarize humoral immune response (anti-HPV 6, 11, 16, 18) induced by V503 or
           GARDASIL.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 1, 2011</start_date>
  <completion_date type="Actual">December 20, 2011</completion_date>
  <primary_completion_date type="Actual">December 20, 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) to HPV Types 16 and 18</measure>
    <time_frame>4 weeks postdose 3 (Month 7)</time_frame>
    <description>Serum antibodies to HPV types 16 and 18 were measured with a Competitive Luminex Immunoassay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GMTs to HPV Types 6 and 11</measure>
    <time_frame>4 weeks postdose 3 (Month 7)</time_frame>
    <description>Serum antibodies to HPV types 6 and 11 were measured with a Competitive Luminex Immunoassay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Are Seropositive for HPV Types 6/11/16/18</measure>
    <time_frame>4 weeks postdose 3 (Month 7)</time_frame>
    <description>Serum antibodies to HPV types were measured with a Competitive Luminex Immunoassay. The serostatus cutoffs (milli Merck Units/mL) for HPV types were as follows: HPV Type 6: ≥30; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24. The percentage of participants who were seropositive according to these cutoffs was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With One or More Adverse Events</measure>
    <time_frame>Up to Month 7</time_frame>
    <description>An adverse event is defined as any unfavourable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine, is also an adverse event. The percentage of participants with one or more adverse events was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With One or More Injection-site Adverse Reactions</measure>
    <time_frame>Up to 5 days after any vaccination</time_frame>
    <description>The percentage of participants with one or more injection-site adverse reactions (solicited or unsolicited) was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With One or More Systemic Adverse Events</measure>
    <time_frame>Up to 15 days after any vaccination</time_frame>
    <description>The percentage of participants with one or more systemic adverse events was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Maximum Oral Temperature ≥37.8°C</measure>
    <time_frame>Up to 15 days after any vaccination</time_frame>
    <description>The percentage of participants with maximum oral temperature ≥37.8°C was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With One or More Serious Adverse Events</measure>
    <time_frame>Up to Month 7</time_frame>
    <description>A serious adverse event is an adverse event that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is a cancer, or may jeopardize the participant and may require medical or surgical intervention. The percentage of participants with one or more serious adverse events was assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Human Papillomavirus</condition>
  <arm_group>
    <arm_group_label>V503</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GARDASIL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V503</intervention_name>
    <description>9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine</description>
    <arm_group_label>V503</arm_group_label>
    <other_name>9vHPV vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GARDASIL</intervention_name>
    <description>Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine</description>
    <arm_group_label>GARDASIL</arm_group_label>
    <other_name>qHPV vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female from 9 to 15 years old.

          -  Good physical health.

        Exclusion Criteria:

          -  Known allergy to any vaccine component.

          -  History of severe allergic reaction.

          -  Thrombocytopenia or any coagulation disorder that would contraindicate intramuscular
             injections.

          -  Pregnant subject.

          -  Immunocompromised or immunodeficient subject.

          -  Splenectomy.

          -  Receipt of medication / vaccine that may interfere with study assessment.

          -  Fever

          -  History of a positive test for HPV, prior receipt of HPV vaccine or prior
             participation to HPV trial.

          -  Any condition that might interfere with study assessment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Sweden</country>
  </removed_countries>
  <results_reference>
    <citation>Vesikari T, Brodszki N, van Damme P, Diez-Domingo J, Icardi G, Petersen LK, Tran C, Thomas S, Luxembourg A, Baudin M. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls. Pediatr Infect Dis J. 2015 Sep;34(9):992-8. doi: 10.1097/INF.0000000000000773.</citation>
    <PMID>26090572</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2011</study_first_submitted>
  <study_first_submitted_qc>February 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2011</study_first_posted>
  <results_first_submitted>July 24, 2017</results_first_submitted>
  <results_first_submitted_qc>July 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 22, 2017</results_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 603 participants were screened and 600 were randomized</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>V503</title>
          <description>9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
        </group>
        <group group_id="P2">
          <title>GARDASIL</title>
          <description>Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="300"/>
                <participants group_id="P2" count="300"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received ≥1 Dose</title>
              <participants_list>
                <participants group_id="P1" count="300"/>
                <participants group_id="P2" count="300"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="294"/>
                <participants group_id="P2" count="295"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>V503</title>
          <description>9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
        </group>
        <group group_id="B2">
          <title>GARDASIL</title>
          <description>Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="300"/>
            <count group_id="B2" value="300"/>
            <count group_id="B3" value="600"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.6" spread="1.9"/>
                    <measurement group_id="B2" value="12.6" spread="1.9"/>
                    <measurement group_id="B3" value="12.6" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>9 to 12 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13 to 15 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="300"/>
                    <measurement group_id="B2" value="300"/>
                    <measurement group_id="B3" value="600"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) to HPV Types 16 and 18</title>
        <description>Serum antibodies to HPV types 16 and 18 were measured with a Competitive Luminex Immunoassay.</description>
        <time_frame>4 weeks postdose 3 (Month 7)</time_frame>
        <population>All randomized participants. The n values are participants who received all 3 vaccinations within acceptable day ranges, had Month 7 serology to the HPV type within acceptable day ranges, were seronegative to the HPV type at Day 1, and had no protocol violations that interfered with evaluation of immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>V503</title>
            <description>9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>GARDASIL</title>
            <description>Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) to HPV Types 16 and 18</title>
          <description>Serum antibodies to HPV types 16 and 18 were measured with a Competitive Luminex Immunoassay.</description>
          <population>All randomized participants. The n values are participants who received all 3 vaccinations within acceptable day ranges, had Month 7 serology to the HPV type within acceptable day ranges, were seronegative to the HPV type at Day 1, and had no protocol violations that interfered with evaluation of immune response.</population>
          <units>milli Merck Units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV Type 16 (n=276, 270)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6739.5" lower_limit="6134.5" upper_limit="7404.1"/>
                    <measurement group_id="O2" value="6887.4" lower_limit="6220.8" upper_limit="7625.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV Type 18 (n=276, 269)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1956.6" lower_limit="1737.3" upper_limit="2203.7"/>
                    <measurement group_id="O2" value="1795.6" lower_limit="1567.2" upper_limit="2057.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HPV Type 16</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority required that the lower bound of the two-sided confidence interval (CI) of the GMT ratio was &gt;0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>GMT Ratio</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT (V503) / GMT (Gardasil)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HPV Type 18</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority required that the lower bound of the two-sided confidence interval (CI) of the GMT ratio was &gt;0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>GMT Ratio</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
            <estimate_desc>GMT ratio = GMT (V503) / GMT (Gardasil)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTs to HPV Types 6 and 11</title>
        <description>Serum antibodies to HPV types 6 and 11 were measured with a Competitive Luminex Immunoassay.</description>
        <time_frame>4 weeks postdose 3 (Month 7)</time_frame>
        <population>All randomized participants. The n values are participants who received all 3 vaccinations within acceptable day ranges, had Month 7 serology to the HPV type within acceptable day ranges, were seronegative to the HPV type at Day 1, and had no protocol violations that interfered with evaluation of immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>V503</title>
            <description>9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>GARDASIL</title>
            <description>Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>GMTs to HPV Types 6 and 11</title>
          <description>Serum antibodies to HPV types 6 and 11 were measured with a Competitive Luminex Immunoassay.</description>
          <population>All randomized participants. The n values are participants who received all 3 vaccinations within acceptable day ranges, had Month 7 serology to the HPV type within acceptable day ranges, were seronegative to the HPV type at Day 1, and had no protocol violations that interfered with evaluation of immune response.</population>
          <units>milli Merck Units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV Type 6 (n=273, 261)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1679.4" lower_limit="1518.9" upper_limit="1856.9"/>
                    <measurement group_id="O2" value="1565.9" lower_limit="1412.2" upper_limit="1736.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV Type 11 (n=273, 261)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1315.6" lower_limit="1183.8" upper_limit="1462.0"/>
                    <measurement group_id="O2" value="1417.3" lower_limit="1274.2" upper_limit="1576.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Are Seropositive for HPV Types 6/11/16/18</title>
        <description>Serum antibodies to HPV types were measured with a Competitive Luminex Immunoassay. The serostatus cutoffs (milli Merck Units/mL) for HPV types were as follows: HPV Type 6: ≥30; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24. The percentage of participants who were seropositive according to these cutoffs was assessed.</description>
        <time_frame>4 weeks postdose 3 (Month 7)</time_frame>
        <population>All randomized participants. The n values are participants who received all 3 vaccinations within acceptable day ranges, had Month 7 serology to the HPV type within acceptable day ranges, were seronegative to the HPV type at Day 1, and had no protocol violations that interfered with evaluation of immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>V503</title>
            <description>9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>GARDASIL</title>
            <description>Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Are Seropositive for HPV Types 6/11/16/18</title>
          <description>Serum antibodies to HPV types were measured with a Competitive Luminex Immunoassay. The serostatus cutoffs (milli Merck Units/mL) for HPV types were as follows: HPV Type 6: ≥30; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24. The percentage of participants who were seropositive according to these cutoffs was assessed.</description>
          <population>All randomized participants. The n values are participants who received all 3 vaccinations within acceptable day ranges, had Month 7 serology to the HPV type within acceptable day ranges, were seronegative to the HPV type at Day 1, and had no protocol violations that interfered with evaluation of immune response.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV Type 6 (n=273, 261)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98.7" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98.6" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV Type 11 (n=273, 261)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98.7" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98.6" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV Type 16 (n=276, 270)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98.7" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98.6" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV Type 18 (n=276, 269)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98.7" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98.6" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With One or More Adverse Events</title>
        <description>An adverse event is defined as any unfavourable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine, is also an adverse event. The percentage of participants with one or more adverse events was assessed.</description>
        <time_frame>Up to Month 7</time_frame>
        <population>All participants who received at least one study vaccination and had safety follow-up data</population>
        <group_list>
          <group group_id="O1">
            <title>V503</title>
            <description>9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>GARDASIL</title>
            <description>Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With One or More Adverse Events</title>
          <description>An adverse event is defined as any unfavourable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine, is also an adverse event. The percentage of participants with one or more adverse events was assessed.</description>
          <population>All participants who received at least one study vaccination and had safety follow-up data</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" lower_limit="87.9" upper_limit="94.5"/>
                    <measurement group_id="O2" value="93.7" lower_limit="84.1" upper_limit="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With One or More Injection-site Adverse Reactions</title>
        <description>The percentage of participants with one or more injection-site adverse reactions (solicited or unsolicited) was assessed.</description>
        <time_frame>Up to 5 days after any vaccination</time_frame>
        <population>All participants who received at least one study vaccination and had safety follow-up data</population>
        <group_list>
          <group group_id="O1">
            <title>V503</title>
            <description>9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>GARDASIL</title>
            <description>Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With One or More Injection-site Adverse Reactions</title>
          <description>The percentage of participants with one or more injection-site adverse reactions (solicited or unsolicited) was assessed.</description>
          <population>All participants who received at least one study vaccination and had safety follow-up data</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.6" lower_limit="87.9" upper_limit="94.5"/>
                    <measurement group_id="O2" value="88.3" lower_limit="84.1" upper_limit="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With One or More Systemic Adverse Events</title>
        <description>The percentage of participants with one or more systemic adverse events was assessed.</description>
        <time_frame>Up to 15 days after any vaccination</time_frame>
        <population>All participants who received at least one study vaccination and had safety follow-up data</population>
        <group_list>
          <group group_id="O1">
            <title>V503</title>
            <description>9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>GARDASIL</title>
            <description>Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With One or More Systemic Adverse Events</title>
          <description>The percentage of participants with one or more systemic adverse events was assessed.</description>
          <population>All participants who received at least one study vaccination and had safety follow-up data</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.5" lower_limit="41.7" upper_limit="53.3"/>
                    <measurement group_id="O2" value="52.0" lower_limit="46.2" upper_limit="57.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Maximum Oral Temperature ≥37.8°C</title>
        <description>The percentage of participants with maximum oral temperature ≥37.8°C was assessed.</description>
        <time_frame>Up to 15 days after any vaccination</time_frame>
        <population>All participants who received at least one study vaccination and had safety follow-up data</population>
        <group_list>
          <group group_id="O1">
            <title>V503</title>
            <description>9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>GARDASIL</title>
            <description>Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Maximum Oral Temperature ≥37.8°C</title>
          <description>The percentage of participants with maximum oral temperature ≥37.8°C was assessed.</description>
          <population>All participants who received at least one study vaccination and had safety follow-up data</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="4.1" upper_limit="10.1"/>
                    <measurement group_id="O2" value="3.3" lower_limit="1.6" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With One or More Serious Adverse Events</title>
        <description>A serious adverse event is an adverse event that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is a cancer, or may jeopardize the participant and may require medical or surgical intervention. The percentage of participants with one or more serious adverse events was assessed.</description>
        <time_frame>Up to Month 7</time_frame>
        <population>All participants who received at least one study vaccination and had safety follow-up data</population>
        <group_list>
          <group group_id="O1">
            <title>V503</title>
            <description>9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>GARDASIL</title>
            <description>Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With One or More Serious Adverse Events</title>
          <description>A serious adverse event is an adverse event that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is a cancer, or may jeopardize the participant and may require medical or surgical intervention. The percentage of participants with one or more serious adverse events was assessed.</description>
          <population>All participants who received at least one study vaccination and had safety follow-up data</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events: up to 15 days after each vaccination; serious adverse events: up to Month 7</time_frame>
      <group_list>
        <group group_id="E1">
          <title>V503</title>
          <description>9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
        </group>
        <group group_id="E2">
          <title>GARDASIL</title>
          <description>Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Complex partial seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary vasculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="299"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Henoch-Schonlein purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="280" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="274" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="299"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection-site erythema</sub_title>
                <counts group_id="E1" events="132" subjects_affected="102" subjects_at_risk="299"/>
                <counts group_id="E2" events="129" subjects_affected="88" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Injection-site pain</sub_title>
                <counts group_id="E1" events="675" subjects_affected="269" subjects_at_risk="299"/>
                <counts group_id="E2" events="626" subjects_affected="266" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Injection-site swelling</sub_title>
                <counts group_id="E1" events="226" subjects_affected="144" subjects_at_risk="299"/>
                <counts group_id="E2" events="160" subjects_affected="109" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="299"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="299"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="84" subjects_affected="57" subjects_at_risk="299"/>
                <counts group_id="E2" events="93" subjects_affected="57" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="299"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

